Azura Ophthalmics
Developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction , the leading cause of Dry Eye Disease.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD124—185m (Dealroom.co estimates Oct 2020.)
Tel Aviv-Yafo Tel Aviv District (HQ)
Authorizing premium user...